Kyowa Hakko Kirin Co., Ltd.

Jun 29, 2020

Kyowa Kirin Names Finance Executive Ana Bastiani-Posner as Executive Vice President, Chief Financial Officer, North America

Jun 03, 2019

Kyowa Kirin Presents Post-Hoc Analysis of Pivotal Trial for Poteligeo® (mogamulizumab-kpkc)

Feb 07, 2019

Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

Dec 03, 2018

Kyowa Kirin Presents Additional Analyses of MAVORIC Trial

Nov 05, 2018

MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan

Aug 10, 2018

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab Published in Lancet Oncology

Aug 08, 2018

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Jun 04, 2018

Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO

Dec 11, 2017

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

Oct 05, 2017

Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin